# Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

> **NCT03393962** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** OC-EIEs

## Key facts

- **NCT ID:** NCT03393962
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-01
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03393962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03393962, "Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03393962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*